Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America

Abstract

it is important to investigate the efficacy and safety profile of fingolimod using ethnically relevant data. Here, we review key data from Hispanic patients enrolled in the fingolimod clinical trial program, summarize recent findings from the FIRST LATAM study, and appraise fingolimod data from real-world patient populations.Funding: Novartis Pharma AG, Basel, Switzerland.

Health Care Cost for Multiple Sclerosis: The Case of a Health Insurer in Colombia

“…In terms of prevalence, it was observed in the literature that the figures reported for Colombia are low compared with those for other countries, which is consistent with the publications that report a high prevalence in countries located beyond the tropical region and a low prevalence in countries that are close to the Equator, such as Colombia [2][3][4][5][6][7][8]46,47]. The prevalence registered for the present study (7.65 per 100,000 affiliates) was higher than the records for prevalence in Colombia [4], which might be related to adverse selection given the characteristics of the target population.…”

“…The prevalence of MS has been historically higher in the United States and Europe compared with Latin American countries and specifically those located in the tropical region. The frequency of this disease has been documented mainly in women with a 2:1 ratio [2][3][4][5]. According to the World Health Organization, it is estimated that more than 2 million people worldwide suffer from MS, which is one of the most common causes of disability in young adults.…”

“…According to the World Health Organization, it is estimated that more than 2 million people worldwide suffer from MS, which is one of the most common causes of disability in young adults. The worldwide and local prevalence of this disease is estimated to range from 15 to 250 per 100,000 inhabitants [1] and from 0.8 to 21.5 per 100,000 inhabitants, respectively, with Argentina and Brazil registering the highest rates [4,5]. The prevalence in Colombia ranges from 1.48 to 4.98 per 100,000 inhabitants depending on the geographic region [4,[6][7][8].…”

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran

“…Confirmation of the effectiveness and safety profile of fingolimod in different ethnic populations is critical to better optimize the MS treatment algorithm. 13 The present study investigated the clinical effectiveness and safety of oral fingolimod in the western Iranian MS population with a relapsing remitting course.…”